RxDoctor Payments Data

Samuel Kugel, MD

Psychiatry · National City, CANPI 1497813968

Payments from drug & device makers

$6,151in general payments, 2019–2025

Across 309 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$4K
  • Sunovion Pharmaceuticals Inc.$790
  • Neurocrine Biosciences, Inc.$411
  • Alkermes, Inc.$313
  • AbbVie$269
  • Otsuka America Pharmaceutical, Inc.$148
  • plus $231 from 4 others

What the payments were for

  • Food & beverage$6,10499%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,151 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$317,915
Medicare patients
284
Services billed
4,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate59$172,587
Risperidone ErRisperidone Microspheres60$135,325
UzedyRisperidone32$105,592
Abilify MaintenaAripiprazole31$86,501
Risperdal ConstaRisperidone Microspheres28$69,881
Lurasidone Hcl81$27,903
VraylarCariprazine Hcl13$18,342
RexultiBrexpiprazole13$18,119
Aripiprazole141$11,363
Clozapine80$10,159
Divalproex Sodium441$9,356
Paliperidone ErPaliperidone62$8,757
Quetiapine Fumarate638$7,204
Haloperidol269$5,922
Quetiapine Fumarate ErQuetiapine Fumarate52$5,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$31$242,46787 claims
Teva Pharmaceuticals USA, Inc.Uzedy$3,990$105,59232 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$148$104,62044 claims
AbbVieVraylar$269$18,34213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in National City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →